Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

766 - HER2 staining intensity has prognostic impact on patients with HER2 type invasive breast cancer

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Hu Yi-Hsuan

Citation

Annals of Oncology (2018) 29 (suppl_8): viii670-viii682. 10.1093/annonc/mdy304

Authors

H. Yi-Hsuan1, L. Yen-Shu2, H. Chih-Yi3, T. Ling-Ming2

Author affiliations

  • 1 Department Of Surgery, Cardinal Tien Hospital, 314334205 - New Taipei/TW
  • 2 Department Of Surgery, Taipei Veterans Hospital, Taipei/TW
  • 3 Department Of Pathology, Taipei Veterans Hospital, Taipei/TW
More

Resources

Abstract 766

Background

Human epidermal growth factor receptor 2 (HER2) is a key marker for breast cancer and HER2-targeted therapy has improved the prognosis for patients with HER2 overexpressed breast cancer. HER2 positivity is defined as HER2 protein overexpression measured by immunohistochemistry (IHC) or HER2 gene amplification evaluated by in situ hybridization (ISH). As the protein expression of HER2 IHC 3+ is higher than that of HER2 IHC 2+, we suppose patients with HER2 IHC 3+ tumor would have better response to anti-HER2 therapy, and their prognosis would better than that of HER2 IHC 2+ tumor. This study aimed to evaluate whether the degree of HER2 IHC positivity affected the outcome of early breast cancer.

Methods

Clinicopathological information of 785 consecutive cases of HER2+ early breast cancer who underwent surgery at Taipei Veterans General Hospital, Taiwan, ROC from 2007 October to 2015 December were retrieved from the medical records. Survival curves were plotted by Kaplan-Meier method, and their differences were calculated by log-rank test. Cox regression model was used to evaluate the hazard of recurrence and death, and the influences of the age of patients, stage, hormonal receptor status, anti-HER2 treatment were adjusted.

Results

Recurrence-free survival of cases with HER2 IHC 3+ tumor was significantly better than that of cases with HER2 IHC 2+ tumor (p = 0.018). Multivariate Cox regression revealed the hazard ratios of cases with HER2 IHC 3+ was significant smaller than those with HER2 IHC 2+ in both RFS (p = 0.001) and OS (p = 0.007).

Conclusions

We confirmed that the intensity of HER2 IHC provided prognostic information for HER2 positive breast cancer. The prognosis of HER2 IHC 3+ cases was significantly better than that of HER2 IHC 2+ and ISH amplified cases. Accurate HER2 testing is important to maximize the benefit of anti-HER2 therapy.

Clinical trial identification

Legal entity responsible for the study

Tseng Ling-Ming.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings